Preexisting Cerebral Microbleeds on Susceptibility-Weighted Magnetic Resonance Imaging and Post-Thrombolysis Bleeding Risk in 392 Patients

• Published in: Stroke (1970) 2014-06, Vol.45 (6), p.1684-1688
• Main Authors: Gratz, Pascal P, El-Koussy, Marwan, Hsieh, Kety, von Arx, Sebastian, Mono, Marie-Luise, Heldner, Mirjam Rachel, Fischer, Urs, Mattle, Heinrich P, Zubler, Christoph, Schroth, Gerhard, Gralla, Jan, Arnold, Marcel, Jung, Simon
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biological and medical sciences; Cerebral Angiography; Cerebral Hemorrhage - diagnostic imaging; Cerebral Hemorrhage - epidemiology; Cerebral Hemorrhage - etiology; Female; Humans; Investigative techniques, diagnostic techniques (general aspects); Magnetic Resonance Angiography; Male; Medical sciences; Middle Aged; Nervous system; Neurology; Prospective Studies; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Risk Factors; Stroke - diagnostic imaging; Stroke - epidemiology; Stroke - therapy; Thrombolytic Therapy - adverse effects; Vascular diseases and vascular malformations of the nervous system
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/STROKEAHA.114.004796

BACKGROUND AND PURPOSE—The question whether cerebral microbleeds (CMBs) visible on MRI in acute stroke increase the risk for intracerebral hemorrhages (ICHs) or worse outcome after thrombolysis is unresolved. The aim of this study was to analyze the impact of CMB detected with pretreatment susceptibility-weighted MRI on ICH occurrence and outcome. METHODS—From 2010 to 2013 we treated 724 patients with intravenous thrombolysis, endovascular therapy, or intravenous thrombolysis followed by endovascular therapy. A total of 392 of the 724 patients were examined with susceptibility-weighted MRI before treatment. CMBs were rated retrospectively. Multivariable regression analysis was used to determine the impact of CMB on ICH and outcome. RESULTS—Of 392 patients, 174 were treated with intravenous thrombolysis, 150 with endovascular therapy, and 68 with intravenous thrombolysis followed by endovascular therapy. CMBs were detected in 79 (20.2%) patients. Symptomatic ICH occurred in 21 (5.4%) and asymptomatic in 75 (19.1%) patients, thereof 61 (15.6%) bleedings within and 35 (8.9%) outside the infarct. Neither the existence of CMB, their burden, predominant location nor their presumed pathogenesis influenced the risk for symptomatic or asymptomatic ICH. A higher CMB burden marginally increased the risk for ICH outside the infarct (P=0.048; odds ratio, 1.004; 95% confidence interval, 1.000–1.008). CONCLUSIONS—CMB detected on pretreatment susceptibility-weighted MRI did not increase the risk for ICH or worsen outcome, even when CMB burden, predominant location, or presumed pathogenesis was considered. There was only a small increased risk for ICH outside the infarct with increasing CMB burden that does not advise against thrombolysis in such patients.